GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Net Change in Cash

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Net Change in Cash : $0.12 Mil (TTM As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

IntelliPharmaCeutics International's Net Change in Cash for the three months ended in Aug. 2023 was $0.24 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2023 was $0.12 Mil.

IntelliPharmaCeutics International Net Change in Cash Historical Data

The historical data trend for IntelliPharmaCeutics International's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Net Change in Cash Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.75 -6.58 0.14 0.57 -0.69

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.20 -0.01 0.09 0.24

IntelliPharmaCeutics International Net Change in Cash Calculation

IntelliPharmaCeutics International's Net Change in Cash for the fiscal year that ended in Nov. 2022 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.388+0.5+0.2+0
=-0.69

IntelliPharmaCeutics International's Net Change in Cash for the quarter that ended in Aug. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=0.241+0+0+0
=0.24

Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International Net Change in Cash Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Net Change in Cash
Comparable Companies
XCNQ:AGN XCNQ:BRAX XCNQ:NOVA TSXV:VXL TSXV:QPT XCNQ:GLOW XCNQ:GTTX TSXV:RP XCNQ:MOOD XCNQ:LOBE OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
I4AA:Germany IPCI:Canada
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
Website
https://www.intellipharmaceutics.com
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.